'Rare innovation to cure a deadly disease' – Gilead gives reasons why Harvoni tops patient spending list

2019_biotech_test_vial_discovery_big

What is behind hepatitis C virus (HCV) drug Harvoni (ledipasvir/sofosbuvir) coming top of a list showing the medicines which accounted for the highest cumulative spending by US patients in 2015?

The drug, marketed by US biotech giant Gilead Sciences (Nasdaq: GILD), led to the most non-discounted spending, according to an  IMS Institute for Healthcare Informatics report.

Its list shows that, in total, $14.3 billion was forked out for Harvoni last year, which is more than the combined 2015 totals of Humira (adalimumab) and Sovaldi (sofosbuvir), which were joint-top in the 2014 list.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology